Novo Not Ready to Quit Alzheimer’s Amid Ozempic Pill Setback (1)

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair of failed trials, saying that patients showed a biological response in a handful of areas despite getting no cognitive improvement.

Doctors found reductions of 10% or less in a handful of markers of neurodegeneration, inflammation and tau, an abnormal protein deposit linked to Alzheimer’s disease, based on measurements of patients’ cerebrospinal fluid, Novo said in a presentation at the Clinical Trials on Alzheimer’s Disease conference on Wednesday in San Diego. There was no change seen in a majority ...